H-CYTE
Business Services · Florida, United States · 1-10 Employees
View Company Info for Free
Overview
Headquarters
201 E Kennedy Blvd Ste 425, Tampa, Flori...Phone Number
(844) 633-6839Website
www.hcyte.comRevenue
<$5 MillionIndustry
ZI Rank: 1
Signal Type
Dec
Jan
Feb
Mar
Apr
May
ZI Rank
1
1
1
1
1
1
About H-CYTE
H-CYTE was formed to build and develop a diversified portfolio of innovative medical technology products and services to improve quality of life for patients. The DenerveX System is H-CYTE's first product and is intended to provide long-lasting relief from pain associated with facet joint syndrome. For biomedical services, H-CYTE manages Lung Health Institute. Lung Health Institute is a leader in regenerative medicine that specializes in cellular therapies to treat chronic obstructive pulmonary disease (COPD) and other chronic lung diseases. In late 2019, H-CYTE's biologics division, LungCYTE, plans to submit an IND to the FDA to study novel and proprietary biologics for treatment of COPD.Explore more
H-CYTE Org Chart
Sell smarter with deeper company insights.
ZoomInfo gives you access to real-time firmographics, buying signals, org charts, and decision-makers - helping your GTM teams prioritize accounts, personalize outreach with AI-driven automation, and close deals faster.
Is H-CYTE your ideal customer? 
Let us give you the heads up on whether it's a good time to reach out
Earning: See what the market has to say on H-CYTE recently announced quarterly report
Congratulate Masked Content for being promoted to Masked Content at H-CYTE
Funding: Get notified immidiatlly once H-CYTE has new funding data
Check if H-CYTE has recently received funding, and reach out quickly before it becomes old news!
Click to see if H-CYTE had a recent Job posting/layoffs
H-CYTE, which may be a good buyer, showed buying intent in Masked Content Topic
Product Launch: Get notified when H-CYTE launches new products
Competitive Alert! Recent activity has been detected by your competitor Masked Content
Check out if H-CYTE is spiking on competitors!
Website visits: Recent activity has been detected on your website
Recommended Actions
Reach out to Masked Content who joined H-CYTE as Masked Content
Find more new buyers
Compare Similar Companies to H-CYTE
Compare insights from companies similar to H-CYTE, focusing on performance, financial data, growth rates, and unique benchmarks to identify key industry trends and opportunities.
Revenue
Number of Employees
Type
Funding
Founded In
Company Profile Activity
Activity Insights
H-CYTE is experiencing very low activity levels compared to other companies in the Business Services sector.
What does this means?
H-CYTE is drawing exceptional interest within the Business Services industry, suggesting notable developments or strong market momentum, learn more about H-CYTE.
H-CYTE financials insights
Gather financial insights about H-CYTE, including details on funding rounds, investors, total funding, and acquisitions, to gain a comprehensive understanding of their financial strategy.
2020
Debt
$350K
H-CYTE Tech Stack
A closer look at the technologies used by H-CYTE
See more technologies
Most Recent Scoops
Mergers & Acquisitions (M&A)
Lateral Move
Executive Move
New Hire
Executive Move
Left Company
Executive Move
Jason Schwieger, Vice President, Sales, has recently left the organization.
Executive Moves, Left Company
Left Company
Executive Move
Executive Moves, Left Company
H-CYTE News & Media
H-CYTE To Acquire SkinDisc
TAMPA, Fla., Sept. 19, 2022 (GLOBE NEWSWIRE) — H-CYTE, Inc., a medical biosciences company, announced today that the Company has... Read More The post H-CYTE To Acquire SkinDisc appeared first on citybiz.H-CYTE Announces Intent to Acquire SkinDisc, Expects to Complete Within 30 Days
Wound Healing and Limb Salvaging Technology Adds to Company’s Asset Portfolio Focused on Unmet Medical Needs Wound Healing and Limb Salvaging Technology Adds to Company’s Asset Portfolio Focused on Unmet Medical NeedsH-CYTE Completes Acquisition of Jantibody
Milestone Achieved as Immunotherapeutic Agent Under Investigation for the Treatment of Ovarian Cancer Added to Asset Portfolio Milestone Achieved as Immunotherapeutic Agent Under Investigation for the Treatment of Ovarian Cancer Added to Asset PortfolioH-CYTE Announces 1-for-1,000 Reverse Stock Split
Strategic Decision to Support Improved Investor Profile and Potential Future Uplisting of Securities to Major ExchangeTAMPA, Fla., June 13, 2022 (GLOBE NEWSWIRE) -- H-CYTE, Inc. (OTCQB: HCYT), a medical biosciences company, today announced that the Board approved a 1-for-1,000 reverse stock split, effective 9:30 a.m. on Monday, June 13, 2022. The Company’s common stock will open for trading on the OTC Exchange on Monday, June 13, 2022 on a split-adjusted basis under the current trading
Read more news
Top Business Services Companies
Top companies in Australia by revenue
Top companies in New Zealand by revenue
Frequently Asked Questions Regarding H-CYTE
Sign Up For FreeTo access detailed company insights
H-CYTE was formed to build and develop a diversified portfolio of innovative medical technology products and services to improve quality of life for patients. The DenerveX System is H-CYTE's first product and is intended to provide long-lasting relief from pain associated with facet joint syndrome. For biomedical services, H-CYTE manages Lung Healt... Read More
